✨ Free AI Report
GRAIL, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview GRAIL, Inc.
Research Preview

GRAIL, Inc.: Business Overview, Financials & Competitive Analysis

GRAIL is a commercial-stage healthcare company developing Galleri, a blood-based multi-cancer early detection test for asymptomatic individuals over 50. The company's mission is to detect cancer early when it can be c...

Analyst-debate audio for GRAIL, Inc.

AskCyborg analysts argue the bull and bear cases for GRAIL, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GRAIL, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Early-stage cancer detection innovator with transformative potential, but clinical validation setbacks and path to profitability...

Read the full analyst-debate transcript →
Industry Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest GRAIL, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

GRAIL, Inc. Overview

Pro stress-test →

GRAIL is a commercial-stage healthcare company developing Galleri, a blood-based multi-cancer early detection test for asymptomatic individuals over 50. The company's mission is to detect cancer early when it can be cured, utilizing next-generation sequencing and machine learning to identify multiple cancer types in earlier stages.

Strategic Profile

Pro stress-test →

GRAIL leverages a targeted methylation-based platform supporting the continuum of care from screening to precision oncology, including minimal residual disease detection and treatment monitoring. The company is positioned as a leader in multi-cancer early detection (MCED), with revenue growing 17% to $147.2M in 2025, though it remains unprofitable as it scales commercial adoption.

Competitive Landscape

Pro stress-test →

GRAIL operates in the emerging MCED space with competitors including Guardant Health (Shield multi-cancer screening), Tempus (precision oncology platform), and Foundation Medicine (oncology diagnostics). GRAIL's differentiation lies in its targeted methylation platform and clinical validation through population-scale studies, though recent trial failures have shifted competitive dynamics.

Industry Context

GRAIL, Inc. operates in Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED).

Key facts

Founded: 2015 · Headquarters: Menlo Park, California · Revenue: $147.2M · Market cap: $5.3B

What the analysts stress-tested

The top findings that survived the multi-agent debate for GRAIL, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when GRAIL, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ShieldMulti-cancer early detection test for asymptomatic adults→Tempus PlatformAI-powered precision oncology and cancer diagnostics→FoundationOneComprehensive genomic profiling for cancer treatment→

Compare GRAIL, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GRAIL, Inc. operates in Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED). See how the rest of the sector scores on the Cyborg framework.

Browse Diagnostics & Cancer Detection - Multi-Cancer Early Detection (MCED) research →
NEW · MCP server

Ask your AI assistant about GRAIL, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GRAIL, Inc. and its top competitor on Cyborg Score”
“What did GRAIL, Inc. do this quarter?”
“Is GRAIL, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GRAIL, Inc. do?+
GRAIL is a commercial-stage healthcare company developing Galleri, a blood-based multi-cancer early detection test for asymptomatic individuals over 50. The company's mission is to detect cancer early when it can be c...
What is GRAIL, Inc.'s Cyborg Score?+
GRAIL, Inc. has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GRAIL, Inc.'s main competitors?+
Named competitors include Shield, Tempus Platform, FoundationOne. The full competitive landscape is in the AskCyborg report.
How can I get the full GRAIL, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GRAIL, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GRAIL, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Phnom Penh Water Supply Authority9ESCO Technologies Inc.9Evolution Mining Limited9CoreWeave, Inc.9Nintendo Co., Ltd.9Waste Management, Inc.9CrowdStrike Holdings, Inc.9SK Hynix Inc.9Kweichow Moutai Co., Ltd.9Apple Inc.8Domino's Pizza, Inc.8Pro-Dex, Inc.8Palladyne AI Corp.8Mo-BRUK S.A.8Kuwait Reinsurance Company K.S.C.P.8Red River Bancshares, Inc.8PTC India Limited8IsoEnergy Ltd.